Earnings ·
LeonaBio reported a net loss of $19.0 million, or $0.80 per share, for the quarter ended June 30, 2026, compared to a…
ATHAAthira Pharma, Inc.
LeonaBio reported a net loss of $19.0 million, or $0.80 per share, for the quarter ended June 30, 2026, compared to a $7.0 million loss in the prior year period. Cash and investments decreased to $51.1 million from $88.3 million at year-end 2025, while R&D expenses rose to $12.9 million due to clinical trial spend for the Phase 3 ELAINE-3 trial of lasofoxifene in metastatic breast cancer. The company remains on track to complete enrollment of approximately 600 patients by the fourth quarter of 2026, with topline data expected in the second half of 2027. Additionally, LeonaBio announced board changes effective May 5, 2026, appointing Fred Callori, Natalie Holles, and Peter Silverman while John Fluke Jr. retired. LeonaBio is a clinical-stage biopharmaceutical company developing novel therapeutics for diseases with high unmet medical needs.